Jaclyn Reynolds, | |
609 N Shore Dr, Bellingham, WA 98226-4414 | |
(360) 676-6000 | |
Not Available |
Full Name | Jaclyn Reynolds |
---|---|
Gender | Female |
Speciality | Counselor - Mental Health |
Location | 609 N Shore Dr, Bellingham, Washington |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1003227174 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
101YM0800X | Counselor - Mental Health | (* (Not Available)) | Primary |
Mailing Address | Practice Location Address |
---|---|
Jaclyn Reynolds, 609 N Shore Dr, Bellingham, WA 98226-4414 Ph: () - | Jaclyn Reynolds, 609 N Shore Dr, Bellingham, WA 98226-4414 Ph: (360) 676-6000 |
News Archive
The high court will hear a challenge to Myriad Genetics' patent of breast and ovarian cancer genes in a case that will affect the future of biomedical research, the fight against diseases like breast and ovarian cancer and a multi-billion dollar biotechnology business.
Bicycle helmets save lives, and their use should be required by law. That's the conclusion of a study to be presented Monday, May 6, at the Pediatric Academic Societies (PAS) annual meeting in Washington, DC.
Almirall, S.A. (ALM:MC) and Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced the launch of Constella® (linaclotide 290mcg capsules once daily), the first approved prescription therapy in a new class of treatments for adults suffering from moderate to severe IBS-C,(1) in Europe. Constella® is now available in Germany, the UK and Nordic countries and is expected to be launched in several other European countries in 2013.
Just weeks after the Food and Drug Administration (FDA) approved Cook Medical's Zilver PTX Drug-Eluting Peripheral Stent, Riverside Methodist Hospital in Columbus, Ohio, has treated the first patient with the device as part of Cook's U.S. commercial launch.
In a recent clinical trial, a gene therapy to treat cerebral adrenoleukodystrophy (CALD) - a neurodegenerative disease that typically claims young boys' lives within 10 years of diagnosis - effectively stabilized the disease's progression in 88 percent of patients, researchers from the Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Massachusetts General Hospital report today.
› Verified 4 days ago
Katharine Margaret Botelle Wolhart, MSW, LICSW Counselor Medicare: Not Enrolled in Medicare Practice Location: 410 W. Bakerview Rd. Suite 110, Office 110, Bellingham, WA 98226 Phone: 360-926-5647 | |
Mr. Keith Poynter, Counselor Medicare: Not Enrolled in Medicare Practice Location: 2530 Kwina Rd, Bellingham, WA 98226 Phone: 360-384-2330 Fax: 360-384-3218 | |
Mr. Richard J Evans V, MA Counselor Medicare: Not Enrolled in Medicare Practice Location: 600 Lakeway Dr, Bellingham, WA 98225 Phone: 360-676-6749 | |
Hollace Carole Schetrompf, Counselor Medicare: Not Enrolled in Medicare Practice Location: 609 N Shore Dr, Bellingham, WA 98226 Phone: 360-676-6000 | |
Ms. Alison Hastings, LMHC Counselor Medicare: Not Enrolled in Medicare Practice Location: 1155 N State St Ste 616, Bellingham, WA 98225 Phone: 360-671-3574 | |
Julie Nelson, CDP-T Counselor Medicare: Not Enrolled in Medicare Practice Location: 515 Lakeway Dr, Bellingham, WA 98225 Phone: 360-676-2187 Fax: 360-676-2162 |